본문 바로가기
KERD
논문KCI 등재

Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma

Andrew Li|Hiang Ping Chan|Phyllis X.L. Gan|Mei Fong Liew|W.S. Fred Wong|Hui-Fang Lim
대한내과학회 (The Korean Association Of Internal Medicine)|2021.11|The Korean Journal of Internal Medicine|제36권 제6호|pp. 1305-1319|DOI https://doi.org/10.3904/kjim.2021.180

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Pulmonary diseaseEosinophiliachronic obstructiveInhaled corticosteroids
주제분류내과학

초록

Approximately 25% to 40% of patients with chronic obstructive pulmonary disease (COPD) have the eosinophilic endotype. It is important to identify this group accurately because they are more symptomatic and are at increased risk for exacerbations and accelerated decline in forced expiratory volume in the 1st second. Importantly, this endotype is a marker of treat ment responsiveness to inhaled corticosteroid (ICS), resulting in decreased mortality risk. In this review, we highlight differences in the biology of eosinophils in COPD compared to asthma and the different definitions of the COPD eosinophilic endotype based on sputum and blood eosinophil count (BEC) with the corresponding limitations. Although BEC is useful as a biomarker for eosinophilic COPD endotype, optimal BEC cutoffs can be combined with clinical characteristics to improve its sensitivity and specificity. A targeted approach comprising airway eosinophilia and appropriate clinical and physiological features may improve identification of subgroups of patients who would benefit from biologic therapy or early use of ICS for disease modification.

Abstract

Approximately 25% to 40% of patients with chronic obstructive pulmonary disease (COPD) have the eosinophilic endotype. It is important to identify this group accurately because they are more symptomatic and are at increased risk for exacerbations and accelerated decline in forced expiratory volume in the 1st second. Importantly, this endotype is a marker of treat ment responsiveness to inhaled corticosteroid (ICS), resulting in decreased mortality risk. In this review, we highlight differences in the biology of eosinophils in COPD compared to asthma and the different definitions of the COPD eosinophilic endotype based on sputum and blood eosinophil count (BEC) with the corresponding limitations. Although BEC is useful as a biomarker for eosinophilic COPD endotype, optimal BEC cutoffs can be combined with clinical characteristics to improve its sensitivity and specificity. A targeted approach comprising airway eosinophilia and appropriate clinical and physiological features may improve identification of subgroups of patients who would benefit from biologic therapy or early use of ICS for disease modification.

참고문헌 (98)

  1. Blanco I, "Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps", Eur Respir J, 54, pp.1900610~ (2019)
  2. George L, "Eosinophilic airway inflammation : role in asthma and chronic obstructive pulmonary disease", Ther Adv Chronic Dis, 7, pp.34~51 (2016)
  3. GBD 2015 Chronic Respiratory Disease Collaborators, "Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015 : a systematic analysis for the Global Burden of Disease Study 2015", Lancet Respir Med, 5, pp.691~706 (2017)
  4. Quaderi SA, "The unmet global burden of COPD", Glob Health Epidemiol Genom, 3, pp.e4~ (2018)
  5. Guarascio AJ, "The clinical and economic burden of chronic obstructive pulmonary disease in the USA", Clinicoecon Outcomes Res, 5, pp.235~245 (2013)
  6. Nunes C, "Asthma costs and social impact", Asthma Res Pract, 3, pp.1~ (2017)
  7. Hurst JR, "Susceptibility to exacerbation in chronic obstructive pulmonary disease", N Engl J Med, 363, pp.1128~1138 (2010)
  8. Kong CW, "Predicting and preventing hospital readmission for exacerbations of COPD", ERJ Open Res, 6, pp.00325-2019~ (2020)
  9. Sprooten RT, "Risk stratification for short-term mortality at hospital admission for acute exacerbations of COPD", Respirology, 24, pp.765~776 (2019)
  10. Weatherall M, "Distinct clinical phenotypes of airways disease defined by cluster analysis", Eur Respir J, 34, pp.812~818 (2009)
  11. Kaur R, "Phenotypes and endotypes of adult asthma : moving toward precision medicine", J Allergy Clin Immunol, 144, pp.1~12 (2019)
  12. Agusti A, "What does endotyping mean for treatment in chronic obstructive pulmonary disease?", Lancet, 390, pp.980~987 (2017)
  13. Singh D, "Eosinophilic inflammation in COPD : prevalence and clinical characteristics", Eur Respir J, 44, pp.1697~1700 (2014)
  14. Bafadhel M, "Acute exacerbations of chronic obstructive pulmonary disease : identification of biologic clusters and their biomarkers", Am J Respir Crit Care Med, 184, pp.662~671 (2011)
  15. Vedel-Krogh S, "Blood eosinophils and exacerbations in chronic obstructive pulmonary disease : the Copenhagen General Population Study", Am J Respir Crit Care Med, 193, pp.965~974 (2016)
  16. Kerkhof M, "Blood eosinophil count and exacerbation risk in patients with COPD", Eur Respir J, 50, pp.1700761~ (2017)
  17. Bafadhel M, "Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease : a post-hoc analysis of three randomised trials", Lancet Respir Med, 6, pp.117~126 (2018)
  18. Agusti A, "Inhaled corticosteroids in COPD: friend or foe?", Eur Respir J, 52, pp.1801219~ (2018)
  19. Pavord ID, "Mepolizumab for eosinophilic chronic obstructive pulmonary disease", N Engl J Med, 377, pp.1613~1629 (2017)
  20. Criner GJ, "Benralizumab for the prevention of COPD exacerbations", N Engl J Med, 381, pp.1023~1034 (2019)
  21. Bruce S Bochner, "Eosinophil Survival and Apoptosis in Health and Disease", Allergy, Asthma & Immunology Research, 2(2), pp.87~101 (2010), 대한천식알레르기학회
  22. Pelaia G, "Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma", Mediators Inflamm, 2015, pp.879783~ (2015)
  23. McBrien CN, "The biology of eosinophils and their role in asthma", Front Med (Lausanne), 4, pp.93~ (2017)
  24. Van Hulst G, "Eosinophil diversity in asthma", Biochem Pharmacol, 179, pp.113963~ (2020)
  25. Amin K, "Role of eosinophil granulocytes in allergic airway inflammation endotypes", Scand J Immunol, 84, pp.75~85 (2016)
  26. Dunican EM, "Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction", J Clin Invest, 128, pp.997~1009 (2018)
  27. Flores-Torres AS, "Eosinophils and respiratory viruses", Viral Immunol, 32, pp.198~207 (2019)
  28. Arora S, "TLRs in pulmonary diseases", Life Sci, 233, pp.116671~ (2019)
  29. Nakagome K, "Involvement and possible role of eosinophils in asthma exacerbation", Front Immunol, 9, pp.2220~ (2018)
  30. Pelaia C, "Severe eosinophilic asthma : from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab", Drug Des Devel Ther, 11, pp.3137~3144 (2017)
  31. Pavord ID, "Mepolizumab for severe eosinophilic asthma(DREAM) : a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)
  32. Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma", N Engl J Med, 360, pp.973~984 (2009)
  33. Chupp GL, "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma(MUSCA) : a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial", Lancet Respir Med, 5, pp.390~400 (2017)
  34. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA) : a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)
  35. Bleecker ER, "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists(SIROCCO) : a randomised, multicentre, placebo-controlled phase 3 trial", Lancet, 388, pp.2115~2127 (2016)
  36. Nair P, "Oral glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)
  37. Kelly EA, "Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma", Am J Respir Crit Care Med, 196, pp.1385~1395 (2017)
  38. Lin A, "Granulocytes : new members of the antigen-presenting cell family", Front Immunol, 8, pp.1781~ (2017)
  39. Doyle AD, "Eosinophil-derived IL-13 promotes emphysema", Eur Respir J, 53, pp.1801291~ (2019)
  40. Daud R, "Elevated serum of ECP in acute exacerbations of COPD", J Chem Pharm Res, 7, pp.401~406 (2015)
  41. Isobe Y, "Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation", Front Immunol, 3, pp.270~ (2012)
  42. "Global strategy for asthma management and prevention 2020" (2021)[URL]
  43. Brightling CE, "Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease : a randomised controlled trial", Lancet, 356, pp.1480~1485 (2000)
  44. Saha S, "Eosinophilic airway inflammation in COPD", Int J Chron Obstruct Pulmon Dis, 1, pp.39~47 (2006)
  45. Petsky HL, "A systematic review and meta-analysis : tailoring asthma treatment on eosinophilic markers(exhaled nitric oxide or sputum eosinophils)", Thorax, 67, pp.199~208 (2012)
  46. Pizzichini E, "Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis", Am J Respir Crit Care Med, 158(5 Pt 1), pp.1511~1517 (1998)
  47. Hargreave FE, "Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 160(5 Pt 2), pp.S53~S57 (1999)
  48. Hastie AT, "Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity : an analysis of the SPIROMICS cohort", Lancet Respir Med, 5, pp.956~967 (2017)
  49. Lim HF, "The evolution of sputum cytometry to assess bronchitis", Can Respir J, 20, pp.415~416 (2013)
  50. Gao P, "The safety of sputum induction in adults with acute exacerbation of COPD", Clin Respir J, 7, pp.101~109 (2013)
  51. Lim HF, "Airway inflammation and inflammatory biomarkers", Semin Respir Crit Care Med, 39, pp.56~63 (2018)
  52. Brightling CE, "Induced sputum and other outcome measures in chronic obstructive pulmonary disease : safety and repeatability", Respir Med, 95, pp.999~1002 (2001)
  53. Beeh KM, "Longterm repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD", Chest, 123, pp.778~783 (2003)
  54. Kolsum U, "Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts", J Allergy Clin Immunol, 140, pp.1181~1184 (2017)
  55. Schleich F, "Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD", Eur Respir J, 47, pp.1562~1564 (2016)
  56. Negewo NA, "Peripheral blood eosinophils : a surrogate marker for airway eosinophilia in stable COPD", Int J Chron Obstruct Pulmon Dis, 11, pp.1495~1504 (2016)
  57. Vestbo J, "Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease(TRINITY) : a double-blind, parallel group, randomised controlled trial", Lancet, 389, pp.1919~1929 (2017)
  58. Papi A, "Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease(TRIBUTE) : a double-blind, parallel group, randomized controlled trial", Lancet, 391, pp.1076~1084 (2018)
  59. Singh D, "Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease(TRILOGY) : a double-blind, parallel group, randomized controlled trial", Lancet, 388, pp.963~973 (2016)
  60. Ferguson GT, "Triple therapy with budesonide", glycopyrrolate, Lancet Respir Med, pp.2018, 6[DOI]
  61. Lipson DA, "Once-daily single-inhaler triple versus dual therapy in patients with COPD", N Engl J Med, 378, pp.1671~1680 (2018)
  62. Rabe KF, "Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD", N Engl J Med, 383, pp.35~48 (2020)
  63. Watz H, "Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids : a post-hoc analysis of the WISDOM trial", Lancet Respir Med, 4, pp.390~398 (2016)
  64. Chapman KR, "Long-term triple therapy de-escalation to indacaterol", glycopyrronium in patients with chronic obstructive pulmonary disease(SUNSET) : a randomized, double-blind, triple-dummy clinical trial, 2018, pp.198, 329~339
  65. Wedzicha JA, "Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk: maybe just for some?", Am J Respir Crit Care Med, 193, pp.937~938 (2016)
  66. Criner GJ, "Predicting response to benralizumab in chronic obstructive pulmonary disease : analyses of GALATHEA and TERRANOVA studies", Lancet Respir Med, 8, pp.158~170 (2020)
  67. Pascoe S, "Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease : analysis of the IMPACT trial", Lancet Respir Med, 7, pp.745~756 (2019)
  68. Oshagbemi OA, "Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts", Am J Respir Crit Care Med, 195, pp.1402~1404 (2017)
  69. Schumann DM, "Stability of the blood eosinophilic phenotype in stable and exacerbated COPD", Chest, 156, pp.456~465 (2019)
  70. Soter S, "Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide", Inflammation, 36, pp.1178~1185 (2013)
  71. Mostafavi-Pour-Manshadi SM, "Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease(COPD)and asthma-COPD overlap(ACO) : a scoping review", COPD, 15, pp.377~391 (2018)
  72. Hancox RJ, "Associations between blood eosinophils and decline in lung function among adults with and without asthma", Eur Respir J, 51, pp.1702536~ (2018)
  73. Ko FW, "Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations", Respirology, 25, pp.259~266 (2020)
  74. Casanova C, "Prevalence of persistent blood eosinophilia : relation to outcomes in patients with COPD", Eur Respir J, 50, pp.1701162~ (2017)
  75. MacDonald MI, "Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD", Chest, 156, pp.92~100 (2019)
  76. Vedel-Krogh S, "Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD", Eur Respir J, 51, pp.1800120~ (2018)
  77. Pavord ID, "Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease : a patient-level meta-analysis", Lancet Respir Med, 4, pp.731~741 (2016)
  78. Kolsum U, "Blood and sputum eosinophils in COPD : relationship with bacterial load", Respir Res, 18, pp.88~ (2017)
  79. "Global strategy for diagnosis, management, and prevention of COPD" (2021)[URL]
  80. Papi A, "Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study", Am J Respir Crit Care Med, 197, pp.1223~1226 (2018)
  81. Pascoe S, "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease : a secondary analysis of data from two parallel randomised controlled trials", Lancet Respir Med, 3, pp.435~442 (2015)
  82. Suissa S, "Inhaled corticosteroids in COPD and the risk of serious pneumonia", Thorax, 68, pp.1029~1036 (2013)
  83. Pauwels RA, "Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease", N Engl J Med, 340, pp.1948~1953 (1999)
  84. Loppow D, "In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation", Respir Med, 95, pp.115~121 (2001)
  85. Jen R, "Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease : a systematic review and meta-analysis", Int J Chron Obstruct Pulmon Dis, 7, pp.587~595 (2012)
  86. Tsang KW, "Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis", Am J Respir Crit Care Med, 158, pp.723~727 (1998)
  87. Bafadhel M, "Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease : a randomized placebo-controlled trial", Am J Respir Crit Care Med, 186, pp.48~55 (2012)
  88. Niewoehner DE, "Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group", N Engl J Med, 340, pp.1941~1947 (1999)
  89. Tantucci C, "Inhaled corticosteroids in COPD : trying to make a long story short", Int J Chron Obstruct Pulmon Dis, 15, pp.821~829 (2020)
  90. Gibson PG, "The overlap syndrome of asthma and COPD: what are its features and how important is it?", Thorax, 64, pp.728~735 (2009)
  91. de Marco R, "Asthma, COPD and overlap syndrome : a longitudinal study in young European adults", Eur Respir J, 46, pp.671~679 (2015)
  92. Ghebre MA, "Biological clustering supports both"Dutch"and"British"hypotheses of asthma and chronic obstructive pulmonary disease", J Allergy Clin Immunol, 135, pp.63~72 (2015)
  93. Hirai K, "A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype", Clin Exp Allergy, 47, pp.1374~1382 (2017)
  94. Rootmensen G, "Clinical phenotypes of obstructive airway diseases in an outpatient population", J Asthma, 53, pp.1026~1032 (2016)
  95. Hiles SA, "Disease burden of eosinophilic airway disease : comparing severe asthma, COPD and asthma-COPD overlap", Respirology, 26, pp.52~61 (2021)
  96. Kostikas K, "The asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?", Int J Chron Obstruct Pulmon Dis, 11, pp.1297~1306 (2016)
  97. Barrecheguren M, "Identification and definition of asthma-COPD overlap : the CanCOLD study", Respirology, 25, pp.836~849 (2020)
  98. Lange P, "Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study : a prospective population-based analysis", Lancet Respir Med, 4, pp.454~462 (2016)

관련 논문AI추천

Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications심소윤, Hae-Sim Park, Youngwoo Choi대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제4호Phenotype of asthma-chronic obstructive pulmonary disease overlap syndrome이진국대한내과학회 · The Korean Journal of Internal Medicine2015 · 제30권 제4호Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world dataChin Kook Rhee, Kwang‑Ha Yoo, Sumitra Shantakumar, Tim Holbrook, Yein Nam, Yu-Fan Ho대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제1호New targets for type 2-low asthma최영우, 허규영, Hae-Sim Park, Quang Luu Quoc대한내과학회 · The Korean Journal of Internal Medicine2024 · 제39권 제2호Immunologic Basis of Type 2 Biologics for Severe AsthmaChoi Youngwoo, Park Hae-Sim, Sim Soyoon대한면역학회 · Immune Network2022 · 제22권 제6호Stability, variability, and treatment implications of the blood eosinophil count in Korean patients with chronic obstructive pulmonary diseaseHyun Woo Lee대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제1호

이 간행물의 다른 논문 (28건)

Hepatic sinusoidal obstruction syndrome/ veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea원종호, Jae-Ho Yoon, Chul Won Choipp. 1261-1280Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular diseaseFan Yang, Dong Sun, Yousuf Waheedpp. 1281-1293Recent advances in airway imaging using microcomputed tomography and computed tomography for chronic obstructive pulmonary diseaseToyohiro Hirai, Naoya Tanabepp. 1294-1304Optimizing glucose control for diabetic patients undergoing percutaneous coronary interventionHaseong Chang, Sung-Hea Kimpp. 1320-1322Is the anti-centromere antibody a marker for a distinct subset of polyautoimmunity in Sjögren’s syndrome?Yun Jong Leepp. 1323-1326
원문 보기